Secondary analysis of the PRIMA trial in newly diagnosed advanced ovarian cancer: first-line niraparib maintenance showed no difference in overall quality of life versus placebo; disease progression caused sustained quality-of-life deterioration in both arms (post hoc).
Secondary analysis
Shahin et al. Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer